For COVID-19 and vaccination updates, view our information for the community. If you're experiencing symptoms, call your primary care provider.

Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

Alliance A081801

Trial Overview

Official Title

Testing The Addition Of A Type Of Drug Called Immunotherapy To The Usual Chemotherapy Treatment For Non-Small Cell Lung Cancer

Study Purpose

To compare the usual treatment alone to using pembrolizumab plus the usual treatment.  The addition of pembrolizumab to the usual treatment could prevent it from returning.

Diagnosis

Patients who had non-small cell lung cancer removed and your cancer has a change in the gene called the PD-L1 gene.

Eligibility

Completely resected Stage IB (>=4cm) or II-IIIA NSCLC enrolled in Alchemist, ECOG 0-1.

Must be 30-77 days post-op.

Patients can have radiation therapy after initial therapy, (-) EFGR/ALK.

Patients must sign an approved informed consent and authorization permitting release of personal health information.

Intervention

Group l: Patients will get the usual drug used to treat this type of cancer

Group 2:  Patients will get the usual drug used to treat this type of cancer, then 17 treatments with pembrolizumab

Group 3: Patients will get the usual drug along with the pembrolizumab, then 13 more pembrolizumab treatments

For more information, visit ClinicalTrials.gov

Key Participation Requirements
Gender
Male or Female
Age
19 years and older
Phase
Phase III
Methodist Health System Trial Code
A081801